TABLE 2:
Relative risk of adverse events between doxycycline and placebo arms of randomized controlled trials
| Outcome | κ | Relative risk (95% CI) | I2% | P-value |
|---|---|---|---|---|
| Included RCT studies | ||||
| Any AE | 9 | 1.03 (0.89, 1.21) | 59.6 | 0.66 |
| Severe AE | 12 | 0.83 (0.59, 1.16) | 2.20 | 0.28 |
| Neurological AE | 11 | 0.88 (0.73, 1.05) | 0.90 | 0.15 |
| Gastrointestinal AE | 12 | 1.68 (1.19, 2.38) | 72.2 | <0.01 |
| Dermatological AE | 9 | 3.55 (1.39, 9.01) | 45.9 | 0.01 |
| Dropped due to AE | 18 | 1.62 (1.12, 2.34) | 7.50 | 0.01 |
| 100 – 200 mg dosages | ||||
| Any AE | 3 | 1.35 (0.69, 2.64) | 74.7 | 0.38 |
| Severe AE | 6 | 0.94 (0.65, 1.34) | 0.00 | 0.73 |
| Neurological AE | 5 | 0.99 (0.97, 1.02) | 0.17 | 0.68 |
| Gastrointestinal AE | 6 | 1.78 (1.16, 2.74) | 81.9 | 0.01 |
| Dermatological AE | 4 | 5.52 (1.75, 17.42) | 68.3 | <0.01 |
| Dropped due to AE | 10 | 1.82 (1.06, 3.11) | 20.9 | 0.03 |
κ = number of studies; AE = adverse event; I2 variation across studies because of heterogeneity rather than chance; CI = confidence interval; RCT = randomized controlled trial